# Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

> **NCT00129740** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 148 (actual)

## Conditions studied

- Leukemia, Myelogenous, Chronic

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT00129740
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-27
- **Primary completion:** 2018-07-11
- **Final completion:** 2018-07-11
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129740, "Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00129740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*